NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022.
| Roivant Investor Day presentation details: | |
| Date: | Wednesday, September 28th, 2022 |
| Time: | 11:15 am Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com. |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Chau Cheng, PhD, MBA
VP Investor Relations
Immunovant, Inc.
info@immunovant.com
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton)…
Montreal-based Thought Technology Ltd wraps up its 50th year in business providing psychophysiological instrumentation to…
The new research from eye care nonprofit Orbis International, supported by Heidelberg Engineering, shows how…